PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023


#226545

196pages

GlobalData

$ 6995

In Stock

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

 

As in the other seven countries covered in this report, Herceptin is the market leader in France, since it was the first HER2-targeting agent to market. Newly-approved drugs tend to gain market access faster in Germany than in the other four EU countries, and this is reflected in the use of Perjeta and Kadcyla in the German HER2-positive breast cancer market. In 2013, Herceptin was the market leader, accounting for 94% of sales in the Italian HER2-positive market. There will be an increase in the breast cancer market size in Spain during the forecast period due to the increased use of HER2-targeted therapies in the neoadjuvant setting, in particular, Perjeta, which is already approved for use in this setting in the US.

 

Scope

 

  • An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the 5EU HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for HER2-Positive Breast Cancer.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the HER2-Positive Breast Cancer sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons To Buy

 

  • Understand the trends shaping and driving the 5EU HER2-Positive Breast Cancer market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the 5EU HER2-Positive Breast Cancer market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What’s the next big thing in the 5EU HER2-Positive Breast Cancer market landscape? Identify, understand and capitalize.

Table of Contents

 

1 Table of Contents 6

1.1 List of Tables 10

1.2 List of Figures 14

 

2 Introduction 15

2.1 Catalyst 15

2.2 Related Reports 16

2.3 Upcoming Related Reports 17

 

3 Disease Overview 18

3.1 Etiology and Pathophysiology 18

3.1.1 Etiology 18

3.1.2 Pathophysiology 18

3.2 Basic Breast Anatomy 20

3.3 Breast Cancer Staging 21

3.4 Prognosis 22

3.5 Quality of Life 23

3.6 Symptoms 25

 

4 Disease Management 26

4.1 Treatment Overview 26

4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 26

4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) 27

4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 30

4.2 France 32

4.2.1 Diagnosis 32

4.2.2 Clinical Practice 33

4.3 Germany 35

4.3.1 Diagnosis 35

4.3.2 Clinical Practice 36

4.4 Italy 38

4.4.1 Diagnosis 38

4.4.2 Clinical Practice 38

4.5 Spain 41

4.5.1 Diagnosis 41

4.5.2 Clinical Practice 42

4.6 UK 43

4.6.1 Diagnosis 43

4.6.2 Clinical Practice 44

 

5 Competitive Assessment 47

5.1 Overview 47

5.2 Product Profiles - HER2-Targeted Therapies 48

5.2.1 Herceptin (trastuzumab) 48

5.2.2 Tykerb (lapatinib) 54

5.2.3 Perjeta (pertuzumab) 59

5.2.4 Kadcyla (ado-trastuzumab emtansine, T-DM1) 63

5.3 Product Profiles - General Targeted Therapies 67

5.3.1 Afinitor (everolimus) 67

5.3.2 Xeloda (capecitabine) 71

5.3.3 Avastin (bevacizumab) 74

5.3.4 Halaven (eribulin mesylate) 77

5.3.5 Abraxane (nab-paclitaxel) 80

5.4 Hormonal Agents 83

5.4.1 Tamoxifen 83

5.4.2 Faslodex (fulvestrant) 84

5.4.3 Aromatase Inhibitors 84

 

6 Unmet Need and Opportunity 86

6.1 Overview 86

6.2 Brain Metastases 87

6.2.1 Unmet Need 87

6.2.2 Gap Analysis 87

6.2.3 Opportunity 89

6.3 Resistance to HER2-Targeting Therapies 89

6.3.1 Unmet Need 89

6.3.2 Gap Analysis 90

6.3.3 Opportunity 91

 

7 Pipeline Assessment 93

7.1 Overview 93

7.2 Promising Drugs in Clinical Development 94

7.2.1 Gilotrif (afatinib) 94

7.2.2 Neratinib 99

7.3 Promising Drugs in Early-Stage Development 103

7.3.1 Palbociclib 105

7.3.2 NeuVax (nelipepimut-S) 109

7.3.3 Patritumab 113

7.3.4 Ganetespib 116

7.3.5 ARRY-380 (ONT-380) 119

7.3.6 NVP-BYL719 122

7.4 Biosimilars 124

 

8 Market Outlook 126

8.1 Global Markets 126

8.1.1 Drivers and Barriers - Global Issues 126

8.2 France 129

8.2.1 Forecast 129

8.2.2 Key Events 132

8.2.3 Drivers and Barriers 132

8.3 Germany 134

8.3.1 Forecast 134

8.3.2 Key Events 137

8.3.3 Drivers and Barriers 137

8.4 Italy 139

8.4.1 Forecast 139

8.4.2 Key Events 142

8.4.3 Drivers and Barriers 142

8.5 Spain 144

8.5.1 Forecast 144

8.5.2 Drivers and Barriers 147

8.6 United Kingdom 149

8.6.2 Key Events 152

8.6.3 Drivers and Barriers 152

 

9 Appendix 155

9.1 Bibliography 155

9.2 Abbreviations 172

9.3 Methodology 178

9.4 Forecasting Methodology 178

9.4.1 Diagnosed HER2-Positive Breast Cancer Patients 178

9.4.2 Percent Drug-Treated Patients 179

9.4.3 Drugs Included in Each Therapeutic Class 179

9.4.4 Launch and Patent Expiry Dates 180

9.4.5 General Pricing Assumptions 181

9.4.6 Individual Drug Assumptions 182

9.4.7 Generic Erosion 189

9.4.8 Pricing of Pipeline Agents 189

9.5 Primary Research - KOLs Interviewed for this Report 191

9.6 Primary Research - Prescriber Survey 192

9.7 About the Authors 193

9.7.1 Analyst 193

9.7.2 Therapy Area Director 193

9.7.3 Global Head of Healthcare 194

9.8 About GlobalData 195

9.9 Disclaimer 195

 

Table 1: AJCC Stage Definitions for Breast Cancer 22

Table 2: Prognosis for Breast Cancer in the US 23

Table 3: Treatment Guidelines for HER2-Positive Breast Cancer 32

Table 4: Product Profile - Herceptin 50

Table 5: Clinical Studies for Herceptin in the Adjuvant Setting 52

Table 6: Herceptin SWOT Analysis, 2013 54

Table 7: Product Profile - Tykerb 56

Table 8: Tykerb SWOT Analysis, 2013 58

Table 9: Product Profile - Perjeta 61

Table 10: Perjeta SWOT Analysis, 2013 63

Table 11: Product Profile - Kadcyla 65

Table 12: Kadcyla SWOT Analysis, 2013 67

Table 13: Product Profile - Afinitor 69

Table 14: Afinitor SWOT Analysis, 2013 70

Table 15: Product Profile - Xeloda 72

Table 16: Xeloda SWOT Analysis, 2013 74

Table 17: Product Profile - Avastin 75

Table 18: Summary of Avastin Phase III Clinical Trials in Metastatic Breast Cancer 76

Table 19: Avastin SWOT Analysis, 2013 77

Table 20: Product Profile - Halaven 78

Table 21: Halaven SWOT Analysis, 2013 80

Table 22: Product Profile - Abraxane 81

Table 23: Abraxane SWOT Analysis, 2013 83

Table 24: Summary of Minor Therapeutic Classes Used to Treat HER-2 positive breast cancer, 2013 85

Table 25: Unmet Need and Opportunity in HER2-Positive Breast Cancer 86

Table 26: Product Profile - Gilotrif 96

Table 27: Gilotrif SWOT Analysis, 2014 98

Table 28: Product Profile - Neratinib 100

Table 29: Neratinib SWOT Analysis, 2013 103

Table 30: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2014 104

Table 31: HER2-Positive Breast Cancer - Early-Phase Pipeline, 2014 104

Table 32: Product Profile - Palbociclib 107

Table 33: Palbociclib SWOT Analysis, 2014 109

Table 34: Product Profile - NeuVax 111

Table 35: NeuVax SWOT Analysis, 2014 113

Table 36: Product Profile - Patritumab 114

Table 37: Patritumab SWOT Analysis, 2014 116

Table 38: Product Profile - Ganetespib 117

Table 39: Ganetespib SWOT Analysis, 2014 119

Table 40: Product Profile - ARRY-380 120

Table 41: ARRY-380 SWOT Analysis, 2014 121

Table 42: Product Profile - NVP-BYL719 122

Table 43: NVP-BYL719 SWOT Analysis, 2014 123

Table 44: Trastuzumab Biosimilars, 2014 125

Table 45: Global HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023 126

Table 46: Sales Forecast ($m) for HER2-Positive Breast Cancer in France, 2013-2023 130

Table 47: Key Events Impacting Sales for HER2-Positive Breast Cancer in France, 2013-2023 132

Table 48: French HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023 132

Table 49: Sales Forecast ($m) for HER2-Positive Breast Cancer in Germany, 2013-2023 135

Table 50: Key Events Impacting Sales for HER2-Positive Breast Cancer in Germany, 2013-2023 137

Table 51: German HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023 137

Table 52: Sales Forecast ($m) for HER2-Positive Breast Cancer in Italy, 2013-2023 140

Table 53: Key Events Impacting Sales for HER2-Positive Breast Cancer in Italy, 2013-2023 142

Table 54: Italian HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023 142

Table 55: Sales Forecast ($m) for HER2-Positive Breast Cancer in Spain, 2013-2023 145

Table 56: Key Events Impacting Sales for HER2-Positive Breast Cancer in Spain, 2013-2023 147

Table 57: Spanish HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023 147

Table 58: Sales Forecast ($m) for HER2-Positive Breast Cancer in the UK, 2013-2023 150

Table 59: Key Events Impacting Sales for HER2-Positive Breast Cancer in the UK, 2013-2023 152

Table 60: UK HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023 152

Table 61: HER2-Positive Breast Cancer Incidence, 2013-2023 179

Table 62: HER2-Positive Breast Cancer Drugs, Key Launch Dates 180

Table 63: HER2-Positive Breast Cancer Drugs, Key Patent Expiries 181

Table 64: Average Body Weight and Surface Area Across the 5EU Markets 182

Table 65: Average Annual Cost of Therapy ($) - Herceptin, Adjuvant 183

Table 66: Average Annual Cost of Therapy ($) - Subcutaneous Herceptin, Adjuvant 184

Table 67: Average Annual Cost of Therapy ($) - Perjeta, First Line 185

Table 68: Average Annual Cost of Therapy ($) - Tykerb, First Line 186

Table 69: Average Annual Cost of Therapy ($) - Kadcyla, Second Line 187

Table 70: Average Annual Cost of Therapy ($) - Halaven, Fourth Line 188

Table 71: Average Annual Cost of Therapy ($) - Abraxane, Fourth Line 189

Table 72: Average Annual Cost of Therapy ($) - Neratinib, Third Line 190

Table 73: Physicians Surveyed by Country 192

 

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes 20

Figure 2: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb 55

Figure 3: Active Late-Stage Clinical Trials for Perjeta 60

Figure 4: Active Phase III Clinical Trials for Kadcyla 64

Figure 5: Active Phase III Clinical Trials for Afinitor 68

Figure 6: Clinical Trials for Halaven 78

Figure 7: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2013 94

Figure 8: Gilotrif’s Clinical Development in Breast Cancer 95

Figure 9: Clinical and Commercial Positioning of Gilotrif 98

Figure 10: Neratinib’s Clinical Development 100

Figure 11: Clinical and Commercial Positioning of neratinib. 102

Figure 12: Sales for HER2-Positive Breast Cancer in France by Drug Class, 2013-2023 131

Figure 13: Sales for HER2-Positive Breast Cancer in Germany by Drug Class, 2013-2023 136

Figure 14: Sales for HER2-Positive Breast Cancer in Italy by Drug Class, 2013-2023 141

Figure 15: Sales for HER2-Positive Breast Cancer in Spain by Drug Class, 2013-2023 146

Figure 16: Sales for HER2-Positive Breast Cancer in the UK by Drug Class, 2013-2023 151